WuBlockchain’s WhiteLine Daily said AI is moving past demonstrations of model capability and into a phase where progress is being measured by lab results, commercial orders and cash returns.
Moderna and Merck report positive Phase 3 result for personalized mRNA cancer therapy
On Aug. 19, Moderna and Merck said their personalized mRNA cancer therapy Intismeran, used in combination with Keytruda, met its endpoints for recurrence-free survival and distant metastasis-free survival in a Phase 3 trial.
The trial enrolled 1,137 patients with stage II B to IV melanoma who had already undergone complete surgical resection. WhiteLine Daily described the outcome as the first positive Phase 3 result for both a personalized neoantigen therapy and an mRNA cancer therapy.
The treatment is designed by screening up to 34 neoantigens based on mutation data from each patient’s tumor, then producing an individualized therapy for that patient. Moderna rose about 177% on the day, while Merck gained 12.6%.
WhiteLine Daily said the market was not only pricing in success in one melanoma trial, but also the possibility that the mRNA platform could extend to other cancers. At the same time, it said the 177% jump also reflected heavy short covering, and that the next questions would be the full data package, regulatory filings and whether individualized manufacturing can scale into a viable commercial model.
Anthropic says Claude took part in a protein design experiment
Anthropic disclosed a protein design experiment in which Claude used multiple specialized protein design and structure prediction models. It selected design sites on its own, generated candidate proteins and screened them before Adaptyv Bio and Twist Bioscience produced and tested the outputs.
The experiment produced effective binding proteins for 14 of 15 targets, with success rates ranging from 22% to 35% depending on the testing method. The report also stressed that the work remains an early-stage protein design experiment in drug research and has not yet gone through animal studies or clinical validation.
WhiteLine Daily’s reading was that AI drug discovery is starting to move from computational output into the lab. Models may shorten the time needed to design and screen candidate proteins, but whether those candidates can become drugs still depends on toxicology work, animal testing and clinical trials that take much longer.
Google receives Marvell warrants tied to chip revenue
Marvell granted Google up to 58.97 million warrants with an exercise price of $206.58 per share. If fully exercised, the total value would be about $12.2 billion.
Only about 1.36 million shares vest on a time basis. The rest are split into 240 tranches. From the third quarter of fiscal 2027 through fiscal 2033, one tranche will vest each time Google generates $500 million in custom chip revenue for Marvell. The cooperation covers AI inference accelerators, storage and network controllers, and near-memory computing within the TPU ecosystem.
After the announcement, Marvell rose 9.9% and Broadcom fell 4.6%. WhiteLine Daily said this does not mean Google is immediately investing $12.2 billion. Instead, the structure uses equity upside to tie Google to Marvell’s long-term delivery. At the maximum vesting threshold, the arrangement implies about $120 billion in cumulative revenue, and the market is reassessing how Google’s custom chip orders may be split between Marvell and Broadcom.
SK Hynix plans 40 trillion won buyback and share cancellation
SK Hynix, one of the world’s major memory chip makers, said it will buy back and cancel shares worth 40 trillion won, or about $28.6 billion, over roughly the next three months. The plan covers about 24.07 million shares, equal to 3.3% of shares outstanding, and WhiteLine Daily said it would be the largest share buyback cancellation on record among South Korean listed companies.
The company also raised its shareholder return target for 2025 through 2027 from no more than 50% of cumulative free cash flow to more than 50%. As of the end of the second quarter, SK Hynix held about 69 trillion won in net cash. Its shares rose 13% after the announcement.
WhiteLine Daily said profits generated by AI memory are now beginning to flow directly back to shareholders. With investors questioning how durable AI spending can be, the $28.6 billion buyback signals both management’s view that the stock is undervalued and that the HBM upcycle has already turned into substantial cash on the balance sheet.
Main theme of the day
The report’s conclusion was straightforward: AI is moving from capability displays to result verification. In healthcare, that means experimental and clinical data. In chips, it means long-term orders and cash returns.